Q3 total revenue of $5.1 million, up 28% over the prior year
156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients
Conference call begins at 4:30 p.m. Eastern time today
BOSTON (November 7, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2023. Read more.